Digital Content 
NEWS #PharmaBuzz
27 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/tremfya-guselkumab-the-first-and-only-il-23-inhibitor-with-a-fully-subcutaneous-treatment-regimen-demonstrates-durable-remission-in-crohns-disease-at-two-years-302594372.html
25 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/24/3172775/0/en/TREMFYA-guselkumab-receives-European-Commission-approval-for-subcutaneous-induction-through-to-maintenance-in-adults-with-ulcerative-colitis-now-the-first-IL-23-inhibitor-with-a-fu.html
07 Oct 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/tremfya-guselkumab-is-first-and-only-il-23-inhibitor-to-demonstrate-sustained-clinical-and-endoscopic-outcomes-with-a-fully-subcutaneous-regimen-through-48-weeks-in-ulcerative-colitis-302576330.html
30 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-fda-approves-tremfya-guselkumab-for-the-treatment-of-pediatric-plaque-psoriasis-and-active-psoriatic-arthritis-marking-a-first-and-only-approval-for-an-il-23-inhibitor-302569442.html
20 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/tremfya-guselkumab-achieves-us-approval-for-subcutaneous-induction-in-adults-with-ulcerative-colitis-now-the-first-and-only-il-23-inhibitor-with-a-fully-subcutaneous-regimen-302561993.html
19 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/19/3153234/0/en/TREMFYA-guselkumab-receives-positive-CHMP-opinion-for-subcutaneous-induction-regimen-in-ulcerative-colitis-a-first-for-an-IL-23-inhibitor.html
Share 